Axsome stocktwits.

Stocktwits provides real-time stock, crypto & international market data to keep you up-to-date. Find top news headlines, discover your next trade idea, share & gain insights from traders and investors from around the world, build a watchlist, buy US stocks, & create and manage your portfolio.Sync with Stocktwits. Latest AXSOME THERAPEUTICS (AXSM) stock news, Axsome Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the develo...Overall, Axsome Therapeutics looks poised to earn at least a few approvals in the next two years and grow its revenue long after that. That's why the biotech still looks like a buy right now ...It was developed by Jazz Pharmaceuticals and approved in mid-2019 before being acquired by Axsome for $53 million (plus royalties) on 5/9/22. Sunosi grew revenue 105% in 2021 to $58 million and ...PyTwits is a REST-API Wrapper for the Social Trading Network StockTwits. Written in Python it enables the user to easily interact with StockTwits REST-API. Installation pip install PyTwits Example Usage. Following example finds AAPL symbol and prints symbol label and title. import pytwits def main (): stocktwits = pytwits.

Before we begin, let's review the company's latest financials. Axsome Therapeutics reported its financial results for Q3 2022. Total revenue for the quarter was $16.8 million, driven by US sales ...On October 13, 2023, the stock performance of AXSM (Axsome Therapeutics) was closely watched by investors. The day started with an opening price of $66.38, slightly lower than the previous day’s closing price of $66.51. Throughout the trading day, the stock experienced a range between $65.76 and $66.85. The trading volume for the day was ...Axsome Therapeutics. @axsome. ·. May 9. Since 1949, @MentalHealthAm. has observed May as Mental Health Month. At Axsome we believe this is a time to share information, stories, resources, and fight the stigma that surrounds mental health issues. To learn more, visit: bit.ly/42kFOwR #MentalHealthAwarenessMonth.

Axsome Therapeutics, Inc. (AXSM): $73.06. 0.79 (+1.09%) POWR Rating. Get Rating. Component Grades. Growth. Get Rating. ... Featured Post From StockTwits About AXSM

Analysts Offer Insights on Healthcare Companies: Axsome Therapeutics (AXSM), Edesa Biotech (EDSA) and Harmony Biosciences Holdings (HRMY). Feb. 14, 2023 at 6 ...Bank of America Corporation Common Stock. $30.45 -0.10 0.33%. Axsome Therapeutics, Inc. Common Stock (AXSM) Pre-Market Stock Quotes - Nasdaq offers pre-market quotes and pre-market activity data ...AXSM Earnings Date and Information. Axsome Therapeutics last announced its earnings results on August 7th, 2023. The reported ($1.00) EPS for the quarter, beating the consensus estimate of ($1.24) by $0.24. The business had revenue of $46.70 million for the quarter, compared to analyst estimates of $40.19 million.Bank of America Corporation Common Stock. $30.45 -0.10 0.33%. Axsome Therapeutics, Inc. Common Stock (AXSM) Pre-Market Stock Quotes - Nasdaq offers pre-market quotes and pre-market activity data ...View live Axsome Therapeutics, Inc. chart to track its stock's price action. Find market predictions, AXSM financials and market news.

Plan Highlights: This exclusive service plan includes. Customizable Scrolling Ticker, Portfolio. Manager, News & Trading alerts; Personal chat, email, voice & text support. Best Fit for Your Budget. Monthly - less than 80 cents per day! Yearly - less than 50 cents per day! Free Trial.

View Anastasia Tsiotra's professional profile on LinkedIn. LinkedIn is the world's largest business network, helping professionals like Anastasia Tsiotra discover inside connections to recommended job candidates, industry experts, and business partners.

View Axsome Therapeutics, Inc AXSM investment & stock information. Get the latest Axsome Therapeutics, Inc AXSM detailed stock quotes, stock data, Real-Time ECN, charts, stats and more.Axsome Therapeutics Inc sentiment based on opinions from MotleyFool, SeekingAlpha and others. Sentiment for Axsome Therapeutics Inc is 23.97% more bullish than other Healthcare sector stocks.According to the issued ratings of 11 analysts in the last year, the consensus rating for Axsome Therapeutics stock is Moderate Buy based on the current 2 hold ratings and 9 buy ratings for AXSM. The average twelve-month price prediction for Axsome Therapeutics is $102.40 with a high price target of $180.00 and a low price target of $81.00.6 Wall Street analysts have issued 1 year price objectives for Avadel Pharmaceuticals' stock. Their AVDL share price forecasts range from $11.00 to $25.00. On average, they expect the company's share price to reach $18.14 in the next twelve months. This suggests a possible upside of 77.5% from the stock's current price.Axsome Therapeutics Inc. Axsome Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing novel therapies for the management of central nervous system disorders. Its product candidates include AXS-02 and AXS-06 which are developing for multiple indications.Discover Axsome Therapeutics Inc (AXSM) market and community sentiment, movement in message volume, participation score and buzz level in the Stocktwits community

Video from Greece https://www.greecevideotv.gr Subscribe : https://bit.ly/2LvcOu8 • Facebook : https://www.facebook.com/Greecevideotv• Twitter : https://t...Axsome Therapeutics is developing innovative treatments for CNS conditions. Get information on our current in-market medicines, pipeline, conditions and ...Axsome Therapeutics (AXSM, $67.36) RSI Indicator left the oversold zone on October 05, 2023. Tickeron - Stocks • 6 days ago. Track Axsome Therapeutics Inc (AXSM) Stock Price, Quote, latest community messages, chart, news and other stock related information.Links AXSM StockTwits. Show Market Indexes. Detailed Chart. Chart Settings. Overall. 80%. Bullish. 0%. Trade Quality. Long. 40%. Short. Breakout Long Short. Tap ...83.15 -0.34(-0.41%) Gold 1,894.70 +7.40(+0.39%) Advertisement Axsome Therapeutics, Inc. (AXSM) NasdaqGM - NasdaqGM Real Time Price. Currency in USD Follow 2W 10W 9M 70.19 -0.37 (-0.52%) At close:...

Axsome Contact: Mark Jacobson Chief Operating Officer Axsome Therapeutics, Inc. 22 Cortlandt Street, 16 th Floor New York, NY 10007 Tel: 212-332-3243 Email: [email protected]

Axsome expects that its operating expenses will increase year over year as the Company commercializes Sunosi and Auvelity and continues to advance its pipeline. Commercial Highlights. Auvelity. Axsome commercially launched Auvelity on October 19, 2022. Early prescription trends reflect strong adoption from prescribers and patients.Monitoring bullish and bearish sentiments towards Axsome Therapeutics on Twitter and Stocktwits could help to forecast an upward or downward trend in Axsome Therapeutics stock price. 4:00 PM (UTC) Date:29 September, 2023AXSM Axsome Therapeutics Inc. Find the latest Matterport, Inc. Subscription ... 03 About Feed Sentiment Fundamentals News. Stocktwits Home">Stocktwits Home.Axsome Contact: Mark Jacobson Chief Operating Officer Axsome Therapeutics, Inc. 22 Cortlandt Street, 16th Floor New York, NY 10007 Tel: 212-332-3243 Email: [email protected] latest price target for Axsome Therapeutics ( NASDAQ: AXSM) was reported by Mizuho on Monday, September 25, 2023. The analyst firm set a price target for 100.00 expecting AXSM to rise to ...As a matter of fact, the issue price is at an almost 11% discount to the closing price on Jun 27, wherein the stock closed at $83.37 per share. Axsome’s shares nosedived 2.8% year to date ...What happened. Shares of Axsome Therapeutics ( AXSM 1.84%), a clinical-stage biopharmaceutical company, are rising sharply in response to a brief submission the company sent to the U.S. Securities ...Axsome AXSM announced that it is floating a secondary issue of 3 million shares of its common stock to the public at a price of $75.00 per share (excluding underwriting discounts).

OLD National Bancorp IN lowered its position in Axsome Therapeutics, Inc. (NASDAQ:AXSM – Get Rating) by 34.5% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 17,445 shares of the company’s stock after selling 9,173 shares during the …

However, Axsome’s total revenue reached $94.6M, powered by license revenue of $65.7M and royalty revenue of $0.3M thanks to a licensing agreement with U.K.-based Pharmanovia for sleep disorder ...

StockTwits is a social network designed specifically for traders and investors to share ideas in real-time. The platform adds a nice spin to the old “stock market message boards” model with a more efficient platform and additional features. Read through this review to see if StockTwits is worth your time or if you’re better off avoiding ...1. AXSM Bullish The MACD is curling and AXSM has a gap to fill in the $51 range. The most recent candle closed above the .61 fib level after price consolidation in the $39 range. $38.52 seems like a reasonable support level. Targeting: $43.34, $46.94, $51The MACD is curling and AXSM has a gap to fill in the $51 range.Axsome Contact: Mark Jacobson Chief Operating Officer Axsome Therapeutics, Inc. 22 Cortlandt Street, 16th Floor New York, NY 10007 Tel: 212-332-3243 Email: [email protected] Therapeutics ( AXSM 1.09%), a clinical-stage biotech focused on the development of drugs for central nervous system disorders, had a seriously rough August. The biotech's shares slipped by ...Auvelity is Axsome’s first drug approved by the FDA in August 2021 and launched in October 2022. Sunosi net product sales were $12.9 million for the first quarter of 2023. There were no net ...Axsome Therapeutics saw a drop in short interest in the month of September. As of September 15th, there was short interest totaling 8,120,000 shares, a drop of 1.5% from the previous total of 8,240,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting ...AXSM Axsome Therapeutics Inc 10,959 Watch Alerts $66.47 $0.04 (0.06%) Today $66.40 0.07 (0.10%) After Hours About Feed News Sentiment Earnings Fundamentals Axsome Therapeutics (AXSM, $66.51) Moving Average Convergence Divergence (MACD) Histogram turned negative on October 12, 2023Tickeron - Stocks • about 22 hours agoAxsome reported its Q1'23 earnings yesterday - net loss was $(0.26) per share. The company's 2 commercial products - newly approved Auvelity and Sunosi, acquired from Jazz Pharmaceuticals earned $29m.George Budwell has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Axsome Therapeutics, Bristol Myers Squibb, and Tesla. The Motley Fool recommends DexCom ...Monitoring bullish and bearish sentiments towards Axsome Therapeutics on Twitter and Stocktwits could help to forecast an upward or downward trend in Axsome Therapeutics stock price. 4:00 PM (UTC) Date:29 September, 2023. 0 ...

Axsome Therapeutics Inc (AXSM) sentiment score, message volume, participation score and buzz level Advertisement 3rd Party Ad. Not an offer or recommendation by Stocktwits. See disclosure here or remove ads. AXSM Axsome Therapeutics Inc 10,961 Watch Alerts $66.51 $3.68 (5.24%) Today $68.08 1.57 (2.36%) Pre-Market About Feed News Sentiment EarningsAXSM earnings call for the period ending September 30, 2022. Image source: The Motley Fool. Axsome Therapeutics ( AXSM -4.52%) Q3 2022 Earnings Call. Nov 07, 2022, 8:00 a.m. ET.Nov 6, 2022 · $66.51 $3.68 (5.24%) Today About Feed News Sentiment Earnings Fundamentals Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. Instagram:https://instagram. lake of ozarks water temperaturemarion county detention center kentuckykroger weekly ad paducah kydisney world extended forecast finance.yahoo.com - October 2 at 10:10 AM. Axsome Therapeutics (NASDAQ:AXSM) Stock Price Down 3.7%. americanbankingnews.com - October 1 at 4:12 AM. AXSOME ALERT: Bragar Eagel & Squire, P.C. is Investigating Axsome Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm. cox funeral home oak grove louisianapaws to remember paducah ky Axsome stock has a high Relative Strength Rating of 97, putting shares in the top 3% of all stocks in terms of 12-month performance, according to IBD Digital. Follow Allison Gatlin on Twitter at ... mayandsmith In August, Axsome received FDA approval for its lead pipeline candidate AXS-05, with the trade name of Auvelity, for the treatment of adults with major depressive disorder (MDD), making it the ...Axsome Therapeutics Inc. Axsome Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing novel therapies for the management of central nervous system disorders. Its product candidates include AXS-02 and AXS-06 which are developing for multiple indications.Axsome Contact: Mark Jacobson Chief Operating Officer Axsome Therapeutics, Inc. 22 Cortlandt Street, 16th Floor New York, NY 10007 Tel: 212-332-3243 Email: [email protected]